- Home
- CERO vs BDRX Comparison
CERO vs BDRX Comparison
Compare CERO & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- BDRX
- Stock Information
- Founded
- CERO 2017
- BDRX 2000
- Country
- CERO United States
- BDRX United Kingdom
- Employees
- CERO N/A
- BDRX N/A
- Industry
- CERO
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- BDRX Health Care
- Exchange
- CERO Nasdaq
- BDRX Nasdaq
- Market Cap
- CERO 3.1M
- BDRX 3.6M
- IPO Year
- CERO N/A
- BDRX N/A
- Fundamental
- Price
- CERO $0.59
- BDRX $1.28
- Analyst Decision
- CERO Strong Buy
- BDRX
- Analyst Count
- CERO 1
- BDRX 0
- Target Price
- CERO $11.00
- BDRX N/A
- AVG Volume (30 Days)
- CERO 4.2M
- BDRX 158.8K
- Earning Date
- CERO 05-27-2025
- BDRX 05-23-2025
- Dividend Yield
- CERO N/A
- BDRX N/A
- EPS Growth
- CERO N/A
- BDRX N/A
- EPS
- CERO N/A
- BDRX N/A
- Revenue
- CERO N/A
- BDRX N/A
- Revenue This Year
- CERO N/A
- BDRX N/A
- Revenue Next Year
- CERO N/A
- BDRX N/A
- P/E Ratio
- CERO N/A
- BDRX N/A
- Revenue Growth
- CERO N/A
- BDRX N/A
- 52 Week Low
- CERO $0.53
- BDRX $1.14
- 52 Week High
- CERO $147.00
- BDRX $74.00
- Technical
- Relative Strength Index (RSI)
- CERO 36.01
- BDRX 37.92
- Support Level
- CERO $0.55
- BDRX $1.11
- Resistance Level
- CERO $0.62
- BDRX $1.38
- Average True Range (ATR)
- CERO 0.06
- BDRX 0.09
- MACD
- CERO -0.01
- BDRX 0.01
- Stochastic Oscillator
- CERO 7.74
- BDRX 40.00
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.